Tesamorelin + Ipamorelin: The One Blend With a Licensed Component
Also known as: Tesamorelin + Ipamorelin · Tesa + Ipa · Tesamorelin/Ipamorelin blend
This blend is unusual because one half of it is a licensed drug with real phase-3 data. Tesamorelin is an FDA-approved GHRH analog — approved specifically for reducing excess visceral abdominal fat in HIV-associated lipodystrophy, at 2 mg daily. That is a narrow indication in a specific population, and it is important not to let the approval halo transfer to uses it was never tested for. Pairing it with ipamorelin follows the standard GHRH-plus-GHRP logic. The combination itself has not been studied. Educational only, not medical advice.
What tesamorelin is actually approved for
Tesamorelin is a stabilized analog of human GHRH, approved for the reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy. The trials that earned that approval showed meaningful reductions in visceral fat specifically — the deep abdominal fat around the organs, not subcutaneous fat generally.
That distinction gets lost constantly. The approval is not for fat loss in healthy adults, not for body recomposition, and not for the general population. The population studied had a specific metabolic derangement driven by their condition and its treatment. Whether the same effect size holds in someone without that condition is not something the trials answer.
The visceral-fat effect is nonetheless the most concrete, best-evidenced result of any compound in this blends section — which is precisely why it deserves to be described accurately rather than stretched.
Why a GHRP is added
The same reasoning as every other GHRH blend: tesamorelin signals GH release, ipamorelin removes the somatostatin brake, and the two together produce a larger pulse than either alone. Ipamorelin is chosen for its selectivity — minimal prolactin and cortisol effect.
Half-lives are reasonably compatible here. Tesamorelin runs roughly 26–38 minutes subcutaneously and ipamorelin about two hours, so a daily schedule suits both, unlike the DAC blend.
Worth stating plainly: the tesamorelin trials studied tesamorelin alone. Adding a second compound to a licensed drug does not inherit that drug's evidence base, and it may change the effect in either direction.
What to track
IGF-1 is the standard downstream marker and was monitored in the tesamorelin trials. Fasting glucose and HbA1c matter here more than usual: GH opposes insulin, and glucose effects were an observed consideration in the clinical data.
If visceral fat is the actual goal, waist circumference is a crude but honest proxy that costs nothing to track over time — and unlike scale weight it moves with the thing the drug was shown to affect.
How to track Tesamorelin + Ipamorelin in Stackeddd
Track IGF-1 and fasting glucose together on this one — the first tells you the GH signal is landing, the second is the trade-off that showed up in the clinical data. Waist measurement over time is the cheapest honest read on the visceral-fat question.
Model it yourself · free, no account
Reconstitution Calculator
A blend is one reconstitution that sets the dose of every compound in the vial — get the water volume right once and every draw after it is correct.
Related compounds
Related reading: What peptides can you mix in the same syringe? · Peptide reconstitution math: how much BAC water to add
Frequently asked questions
Is tesamorelin FDA approved?
Yes, but for a specific indication: reducing excess visceral abdominal fat in HIV-associated lipodystrophy, at 2 mg daily. It is not approved for fat loss in healthy adults or for body recomposition, and the trial population had a condition-specific metabolic problem that does not automatically generalise.
Does the blend inherit tesamorelin's clinical evidence?
No. The trials studied tesamorelin on its own. Adding ipamorelin creates a combination that has not been tested, and a second active compound can change an effect in either direction. The approval belongs to the single drug, not to the blend.
Why is tesamorelin paired with ipamorelin?
The standard GHRH-plus-GHRP logic — tesamorelin signals growth-hormone release while ipamorelin suppresses somatostatin, the brake on that release. Their half-lives also suit a shared daily schedule, which is not true of every blend.
This is educational information, not medical advice. Doses and protocols above reflect published references and community practice — protocol decisions belong with your prescribing physician. Generic names used throughout. How this reference is built & how the AI is tested →
STACKEDDD
Track it instead of guessing.
Doses, reconstitution, bloodwork, and an AI coach grounded in your own data — free to start, on the App Store and Google Play.